Efficacy and safety of apatinib treatment for advanced gastric cancer after chemotherapy resistance / 肿瘤
Tumor
;
(12): 356-361, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-848398
ABSTRACT
Objective:
To observe the clinical efficacy and adverse reactions of apatinib in advanced gastric cancer after routine chemotherapy.Methods:
Thirty-one patients with unrespectable stage IV gastric cancer and had a deterioration or recurrence after at least 2 cycles of chemotherapy with thymidine phosphorylase-based regimen, were recruited in this study. The patients were given with 500-250mg of apatinib once daily till disease progression. A chest and abdomen CT or MRI scan was taken every 2 cycles for a response assessment.Results:
Among the 31 patients, no one achieved complete response, 7 patients (22.6%) had partial response, 17 patients (32.3%) had stable disease; the disease control rates was 54.8%. The median time to progression was 4.0 months [95% confidence interval (CI) 3.2-4.8]. The median survival time was 5.3 months (95% CI 3.2-7.4). The main adverse reactions were hypertension, hand foot syndrome, diarrhea, fatigue, proteinuria and liver function damage.Conclusion:
Apatinib can obtain good clinical effect in treatment of advanced gastric cancer after chemotherapy resistant.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Tumor
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS